Patritumab deruxtecan

Patritumab deruxtecan is an investigational antibody-drug conjugate (ADC) designed for the treatment of various types of cancer. It is composed of a fully human anti-HER3 (human epidermal growth factor receptor 3) monoclonal antibody linked to a topoisomerase I inhibitor payload. This drug is being developed by Daiichi Sankyo in collaboration with AstraZeneca.

Mechanism of Action

Patritumab deruxtecan targets the HER3 receptor, which is overexpressed in several types of cancer, including non-small cell lung cancer (NSCLC) and certain types of breast cancer. Upon binding to HER3, the ADC is internalized by the cancer cell, where the linker is cleaved, releasing the cytotoxic payload. The released topoisomerase I inhibitor then induces DNA damage, leading to cell death.

Clinical Development

Patritumab deruxtecan is currently undergoing clinical trials to evaluate its efficacy and safety in various cancer types. Early-phase studies have shown promising results, particularly in patients with advanced or metastatic cancers that have become resistant to other treatments.

Non-Small Cell Lung Cancer

In NSCLC, patritumab deruxtecan is being investigated for its potential to treat patients who have progressed on prior therapies, including tyrosine kinase inhibitors and chemotherapy.

Breast Cancer

For breast cancer, particularly HER3-positive subtypes, patritumab deruxtecan is being studied as a potential treatment option for patients who have exhausted other therapeutic options.

Side Effects

As with other ADCs, patritumab deruxtecan can cause a range of side effects. Common adverse events include nausea, fatigue, and neutropenia. More serious side effects may include interstitial lung disease and severe myelosuppression.

Future Directions

Ongoing research aims to further elucidate the optimal use of patritumab deruxtecan, including combination therapies with other targeted agents and immunotherapies. The results of these studies will determine its potential role in the standard treatment regimens for various cancers.

See Also

• Antibody-drug conjugate
• HER3
• Non-small cell lung cancer
• Breast cancer
• Monoclonal antibody